BridgeBio Pharma, Inc. BBIO
Set alert
76.47 USD +1.47 +1.97%
As of Nov 3, 9:53 AM ET
75.25 Day range 76.66
61.37 52-week range 90.17
- YTD
- -0.03%
- 1 year
- +23.38%
- Open
- 75.50
- Prev close
- 75.00
- Mkt cap
- 14.93B
- Vol
- 341.76K
- Avg vol
- 2.60M
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 75.25
- High
- 76.66
- Forward P/E
- -231.49
- Beta
- 0.94
- Short ratio
- 6.50
- Inst. own
- 99.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2027
- 50-d avg
- 70.27
- 200-d avg
- 72.74
- 1y target
- 107.11
6M chart
Events in this range
- May 7, 2026Earnings: -0.84; estimate -0.67877; surprise -23.75%
- Aug 10, 2026Earnings: -0.78; estimate -0.57558; surprise -35.52%
- Oct 19, 2026Rating: Piper Sandler · Overweight → Overweight
- Oct 19, 2026Rating: Citigroup · Neutral → Neutral
- Oct 21, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 29, 2026Earnings: -0.42; estimate -0.54225; surprise 22.54%
- Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 30, 2026Rating: TD Cowen · Buy → Buy
- Nov 2, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (16)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 4 days ago |
| RSI: Overbought | Oct 30, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Sep 9, 2026 | 1 month ago |
| SMA: Bearish | Aug 26, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
Financial health
Altman Z-Score
-0.07 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -20.2×
FY 2017 5y median -9.5× FY 2025
P/S 30.0×
FY 2017 5y median 30.0× FY 2025
P/B -7.3×
FY 2017 5y median -3.5× FY 2025
P/FCF -33.8×
FY 2017 5y median -9.8× FY 2025
EV/EBITDA -25.5×
FY 2017 5y median -14.0× FY 2025
EV/Sales 34.3×
FY 2017 5y median 34.3× FY 2025
FCF Yield -3.0%
FY 2017 5y median -10.2% FY 2025
Profitability
Gross Margin 94.4%
FY 2017 5y median 95.5% FY 2025
Operating Margin -113.3%
FY 2017 5y median -659.6% FY 2025
Net Margin -145.3%
FY 2017 5y median -619.7% FY 2025
ROE 35.1%
FY 2017 5y median 38.4% FY 2025
ROIC -108.5%
FY 2017 5y median -101.4% FY 2025
ROA -77.9%
FY 2017 5y median -77.2% FY 2025
Growth (YoY)
Revenue 126.3%
FY 2017 FY 2025
Operating Income 4.0%
FY 2017 FY 2025
EPS (diluted) -31.6%
FY 2017 FY 2025
Free Cash Flow 14.3%
FY 2017 FY 2025
Financial Health
Current Ratio 2.6×
FY 2017 5y median 4.5× FY 2025
Quick Ratio 2.5×
FY 2017 5y median 4.5× FY 2025
Debt / Equity -1.3×
FY 2017 5y median -1.3× FY 2025
Net Debt / EBITDA -3.2×
FY 2017 5y median -2.5× FY 2025
Interest Coverage -10.7×
FY 2017 5y median -7.5× FY 2025
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
